Multidrug resistance-associated protein expression in clinical gastric carcinoma
β Scribed by Kazuya Endo; Yoshihiko Maehara; Yuji Ichiyoshi; Tetsuya Kusumoto; Yoshihisa Sakaguchi; Shinji Ohno; Keizo Sugimachi
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 759 KB
- Volume
- 77
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
BACKGROUND.
We examined the relationship between the expression of a multidrug resistance-associated protein (MRP) and the biologic factors regarding invasion and metastasis of human gastric cancer.
METHODS.
In 75 patients with gastric cancer, the expression of MRP was immunohistochemically investigated and the expression of MRP mRNA was also detected using reverse transcription PCR (RT-PCR). Sensitivity to the anticancer agents, cisplatin (CDDP), doxorubicin (DXR), etoposide (VP-16), and mitomycin C (MMC) was examined using the MTT {3-(4,5-dimethyl-2-thiazolyl)-2,5-dipheny1[2H] -tetrazolium bromide) assay. The relation between MRP expression and development, invasion, and metastasis of cancer was analyzed, and overexpression of the tumor suppressor gene p53 was investigated, immunohistochemically.
RESULTS.
Immunohistochemically detected MRP positive tumors were noted in 34 of 75 excised tumors (45%), and confirmed by RT-PCR. There was no significant relation between MRP expression and clinicopathologic features or prognosis. Positive p53 staining was evident in 16 of 34 MRP positive tumors (47%) and 18 of 41 negative ones (44%), and there was no significant correlation between MRP and abnormal p53 expression. The MTT assay showed that MRP positive gastric cancer tissue was less sensitive to CDDP, DXR, and MMC compared with MRP negative ones. A similar tendency was noted with W-16.
CONCLUSIONS.
MRP expression relates to the chemosensitivity of tumor cells against some anticancer drugs and is independent of known factors related to the development, invasion, and metastasis of human gastric cancers.
π SIMILAR VOLUMES
The intrinsic or acquired resistance of urothelial cancer to chemotherapy is one major obstacle to successful treatment. Generally, the expression level of P-glycoprotein in urothelial cancer is low, so we accordingly investigated the expression of multidrug resistance-associated protein (MRP). We e
MRP has been identified as another multidrug-resistance (MDR) gene and may be involved in an alternative MDR mechanism in some solid tumors. We investigated the expres- sion of M R P mRNA in multidrug-resistant KB sublines (KB-8-5, KB-CZ, C -W and C A I to), human non-small-cell lung carcinomas (NSC
BACKGROUND. Multidrug resistance protein (MRP) is a membrane
## BACKGROUND. Overexpression of the multidrug resistance gene (MDR1) product, the MDR1 protein (MDR1), has been associated with poor prognosis in several hematologic malignancies. The significance of MDR1 levels in patients with chronic myeloid leukemia (CML) has not been established. ## METHODS
## Abstract Pancreatic ductal adenocarcinoma is among the top 10 causes of death from cancer in industrialized countries. In comparison with other gastrointestinal malignancies, pancreatic cancer is one of the tumors most resistant to chemotherapy. An important mechanism of tumor multidrug resistan